Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nebivolol - Janseen

Drug Profile

Nebivolol - Janseen

Alternative Names: Bystolic; Lobivon; Nebilet; Nebilox; Nebivolol hydrochloride; R 067555; R 65824; R 67555; Solistar

Latest Information Update: 04 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen L.P.
  • Developer Allergan; Duncan; Forest Laboratories; Janssen; Menarini
  • Class Antihypertensives; Benzopyrans; Ethanolamines; Fluorobenzenes; Heart failure therapies; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic heart failure; Heart failure; Hypertension
  • Discontinued Angina pectoris

Most Recent Events

  • 29 Jan 2019 Kowa Pharmaceuticals America and Allergan agree to commercialise Nebivolol in USA for Hypertension
  • 24 Jun 2018 Biomarkers information updated
  • 19 Jun 2017 Discontinued - Phase-III for Hypertension in USA (PO), because not listed on Allergan pipeline, June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top